News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
Monday, March 10, 2025The Ministry of Health Labor and Welfare MHLW in Japan has granted Orphan Drug Designation ODD to Lundbecks investigational drug amlenetug a potential new treatment option targeting Multiple System Atrophy MSA
Orion and Aiforia extend collaboration to preclinical study evaluations
Thursday, March 06, 2025Orion Corporation and Aiforia Technologies Plc a Finnish medical software company today announced the extension of their collaboration to include the use of Aiforias software solution for preclinical study evaluations This collaboration will involve...
Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
Thursday, March 06, 2025Bioxodes SA a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases has received Orphan Drug Designation ODD for its firstinclass BIOX therapeutic candidate to tre...
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Wednesday, March 05, 2025ACELYRIN INC and Alumis Inc reaffirmed their commitment to merge in an allstock transaction which will create a leading clinical stage biopharma company in immunemediated diseases Martin Babler President Chief Executive Officer and Chairman of Alumis...
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®
Wednesday, March 05, 2025Optime Care a nationally recognized specialty pharmacy and an AscellaHealth Company today announces an expanded partnership with Eton Pharmaceuticals Eton an innovative pharmaceutical company focused on developing and commercializing treatments for r...
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Tuesday, March 04, 2025Pliant Therapeutics Inc announced that following a prespecified data review and recommendation by the trials independent Data Safety Monitoring Board DSMB as well as a secondary review and recommendation by an outside expert panel Pliant has disconti...
Gensaic Announces Collaboration with Novo Nordisk to Unlock Next Generation Precision Therapies
Tuesday, March 04, 2025Gensaic Inc Gensaic a biotechnology company that combines AIpowered protein design with biological insights to discover ligands for tissueselective intracellular delivery today announced a license and discovery collaboration with Novo Nordisk a globa...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Monday, March 03, 2025AbbVie and Gubra AS a company specializing in preclinical contract research services and peptidebased drug discovery within metabolic and fibrotic diseases today announced a license agreement to develop GUB a potential bestinclass
US FDA Grants Priority Review to Sobi's Supplemental Biologics Licence Application for Gamifant
Friday, February 28, 2025Sobi has announced that the US Food and Drug Administration FDA has accepted the supplemental Biologics License Application sBLA for Gamifant emapalumablzsg The application seeks approval for use in adult and paediatric patients with haemophagocytic
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Systemic Sclerosis Treatment
Friday, February 28, 2025Adicet Bio Inc a biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer has received Fast Track Designation from the US Food and Drug Administration FDA for ADI as a potential treatment...
